Targeted therapies and resistance mechanisms of hematologic malignancies报告人:
Beijing Tongren Hospital
Dr. Liang Wang is a Professor in Beijing Tongren Hospital, Capital Medical University. Dr. Wang got his medical doctor degree in Peking Union Medical College in 2010, and spent 10 years in Sun Yat-sen University Cancer Center and Southern Medical University as a physician. Dr. Wang specialized in the diagnosis and treatment of hematologic malignancies, and published more than 30 scientific papers in journals such as Lancet Haematology, Journal of Hematology & Oncology, Clinical Cancer Research, Leukemia, Clinical and Translational Medicine, and so on. Dr. Wang was awarded the 2017-Honorable Doctor-Youth Innovation Award.
In recent years, small molecular novel agents and immunotherapy targeting PD1/PD-L1 have greatly shifted the treatment patterns of hematologic malignancies. However, classical chemotherapy drugs cannot be abandoned due to its high efficacy in first-line setting. It is crucial to investigate the detailed resistance mechanisms and explore the role of novel forms of cytotoxic drugs, such as nanoparticle-delivered drugs or pegylated drugs. Herein, we introduce our research in the treatment and resistance mechanisms of hematologic malignancies: (1) verifying the role of pegylated asparaginase-based therapy in the treatment of NK/T-cell lymphoma; (2) elucidating the mechanisms of resistance to asparaginase in patients with NK/T-cell lymphoma; (3) exploring the potential mechanisms of immune evasion in NK/T-cell lymphoma; (4) targeting Bruton Tyrosine Kinase (BTK) in the treatment of primary intraocular lymphoma; (5) old drugs with new tricks: combination of two nanoparticle-delivered drugs in the treatment of heavily-pretreated diffuse large B cell lymphoma patients.